[A24-64] Bimekizumab (hidradenitis suppurativa) - Benefit assessment according to § 35a Social Code Book V
Last updated 22.11.2024
Project no.:
A24-64
Commission:
Commission awarded on 17.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adult patients with active moderate to severe hidradenitis suppurativa (acne inversa) with an inadequate response to conventional systemic hidradenitis suppurativa therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-64_en
| Project no. | Title | Status |
|---|---|---|
| A23-60 | Bimekizumab (psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-61 | Bimekizumab (ankylosing spondylitis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-110 | Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-62 | Bimekizumab (non-radiographic axial spondyloarthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G24-28 | Bimekizumab (hidradenitis suppurativa) - Addendum to Project A24-64 | Commission completed |
Federal Joint Committee (G-BA)
2024-11-22 A G-BA decision was published.